anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Probiotics can colonize both the human and animal bodies and consist of active microorganisms that are beneficial to health. The use of probiotics has been shown to alleviate certain neurological diseases and disturbances in gut microbiota resulting from chronic ethanol exposure. Research indicates that probiotics can influence the nervous system via the microbial-gut-brain axis, wherein extracellular vesicles secreted by the gut microbiota play a significant role in this process.
RESULTS: In this study, we first established a 30-day ethanol exposure and probiotic gavage mouse model, both of which influenced behavior and the composition of gut microbiota. We then extracted gut microbiota-derived extracellular vesicles from the feces of these model mice and injected them into new mice via the tail vein to assess the role of each set of extracellular vesicles. The results indicated that the extracellular vesicles derived from the intestinal microbiota in the ethanol group induced anxiety-like behavior and hippocampal neuroinflammation in the recipient mice. In contrast, the extracellular vesicles secreted by the gut microbiota from the probiotic group mitigated the anxiety-like behavior and neuroinflammation induced by ethanol-influenced extracellular vesicles.
CONCLUSIONS: Our study demonstrates that extracellular vesicles secreted by the gut microbiota can influence the nervous system via the microbial-gut-brain axis. Furthermore, we found that the extracellular vesicles secreted by the gut microbiota from the probiotic group exert a beneficial therapeutic effect on anxiety and hippocampal neuroinflammation.
Vibration with alternating side of the base, performed at 25 Hz and 4 mm peak-to-peak displacement, for 5 minutes each session, three times a week. Participants will be positioned standing, with knees semi-flexed at 30º.
Risks from Concomitant Use with Opioids

Concomitant use of benzodiazepines, including Restoril, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. 

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Restoril concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. In patients already receiving an opioid analgesic, prescribe a lower initial dose of Restoril than indicated in the absence of an opioid and titrate based on clinical response. If an opioid is initiated in a patient already taking Restoril, prescribe a lower initial dose of the opioid and titrate based upon clinical response. 

Advise both patients and caregivers about the risks of respiratory depression and sedation when Restoril is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been determined (see PRECAUTIONS, Drug Interactions).
A single instillation of pirarubicin (THP) plus one year long-term intravesical instillation after nephroureterectomy was performed. The ﬁrst instillation was initiated within 72-168 hours after surgery, followed by four times weekly and 11 times monthly (16 times in total in one year time) . Every time, THP 30 mg in 30 mL of normal saline was delivered into the bladder through a catheter and was retained for 30 minutes.
PT--80187 A The cpds. are of formula (IV), in which R1 is H or CH3. They are made by hydrolysis of the ester of formula (III) in which R is 1-3C alkyl, which is prepd. by reaction of a cpd. of formula (II) with a cpd. of formula (I), in which X is a halogen atom. EPAB- EP-195135 B A process for the preparation of a compound of the formula (IV) wherein R1 is a hydrogen atom or a methyl group, which comprises saponifying a compound of the formula (III), wherein R1 is a hydrogen atom or a methyl group, which is prepared by the reaction of a compound of the formula (II), wherein R1 has the above-stated meaning, with a compound of the formula (I) which is prepared by the reaction of a compound of the formula (V), with 2-fluoroethyl tosylate.
The eye of interest will first receive three consecutive intravitreal injections of 0.5 mg conbercept every 4 weeks, then the researcher will determine the next follow-up visit time/treatment interval based on results of each follow-up assessment as per the "treatment-extended dosing criteria". When the follow-up/treatment interval of the subject is extended to 12 weeks, additional safety follow-up visit can be arranged if any suspicious active lesion is deemed by the researcher; additional injection can be given if the result of safety follow-up assessment meets the "extra dosing criteria".
In the mobile phone group, patients were asked to continue their exercise program at home at a fixed walking speed. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
A method and apparatus are provided for configurable logging and analysis of performance data for a medical diagnostic imaging system. A medical diagnostic imaging system may be divided into at least one subsystem. The subsystems include data acquisition modules for acquiring desired types of data related to the performance of an associated subsystem. The data acquisition modules acquire raw performance data during the operation of the medical diagnostic imaging system. The data acquisition modules may remotely acquire the raw performance data. The raw performance data may be acquired based upon a configuration file which identifies parameters associated with a desired type of performance analysis. New configuration files may be downloaded to dynamically select at least one parameter for a desired type of performance analysis. Parameters in the configuration file may comprise at least one of a performance variable and a sampling rate for the performance variable. A processing module processes the raw performance data acquired by the data acquisition modules. Data may be processed in real-time during the operation of the medical diagnostic imaging system. The processing module produces characteristic data summarizing the raw performance data. For example, the processing module may calculate trend statistics or perform statistical analyze on the raw performance data to produce characteristic data.
Postterm pregnancy is defined as a pregnancy that has reached 42 weeks' gestation and late-term pregnancy includes 41 weeks' and 0 days' to 41 weeks' and 6 days' gestation. Accurate first-trimester dating is essential for determining or verifying gestational age. Ideal management of late-term and postterm pregnancy involves shared decision-making on timing of planned delivery based on risks and preferences. Starting at 42 weeks' gestation, the risks of fetal mortality, admission to the neonatal intensive care unit, and stillbirth increase exponentially. Induction of labor at 41 weeks' gestation reduces perinatal mortality and stillbirth compared with expectant management or induction starting at 42 weeks' gestation. Recent studies have shown a decrease in cesarean deliveries and hypertensive disorders of pregnancy with induction of labor in nulliparous, low-risk pregnancies beginning at 39 weeks' gestation. Induction of labor before 42 weeks' gestation decreases the risk of stillbirth, perinatal mortality, and cesarean delivery compared with expectant management. The American College of Obstetricians and Gynecologists suggests considering an elective induction of labor in low-risk, nulliparous patients starting at 39 weeks' and 0 days' gestation and recommends induction of labor in all patients by 42 weeks' gestation. The American College of Obstetricians and Gynecologists recommends antepartum monitoring of pregnancies beginning at 41 weeks' gestation to mitigate the risks of perinatal morbidity and mortality.
PURPOSE:To obtain the subject compound which is a stereoisomer derivative of epibatidine extracted from skin of a toxic frog and having nonopioid analgesic action in high yield by subjecting a compound having a specific structure to deprotection. CONSTITUTION:An endo-halopyridyl-N-protected azabicycloheptane of formula I (R<1> is formyl, allyl, etc.; R<2> is halogen) {e.g. endo-2-(6'-chloro-3'-pyridyl)-7- ethoxycarbonylazabicyc lo-[2.2.1]heptane} is deprotected to provide the objective compound of formula II (X is anion). The protection is preferably carried out by catalytic reduction or acid hydrolysis using hydrochloric acid, etc. Furthermore, the compound of formula I is preferably obtained by successively carrying out reduction, hydrolysis, introduction of N-protecting group, formation of sulfonic acid ester, deprotection and base treatment using a compound of formula III as a starting raw material, introducing a N-protecting group to the produced compound of formula IV, treating the resultant compound with a peracid, etc., and successively reacting the resultant compound of formula V with a halogenating agent.
All other patients, i.e. (i) patients in whom most or ≥3 lesions display a FES SUVmax \<2 that are not amenable to local treatment, (ii) patients with high levels of circulating tumor biomarkers, will be randomized between chemotherapy in Arm B and endocrine therapy in Arm C.
HER2 positive (Immunohistochemistry (IHC) 2+ with fluorescence in situ hybridization (FISH) confirmation and Immunohistochemistry (IHC) 3+) breast cancer. Treatment with A166 at recommended Phase II dose.
PURPOSE: A method for preparing a discrete stanol/sterol-ester by direct esterification of stanol or sterol with a fatty acid provides a synthesis rout adequate to the mass production of a pure stanol/sterol ester having the formula 1 at high yield. CONSTITUTION: The method comprises adding a stanol/sterol represented by the formula 2 and an acid; and reacting the stanol/sterol with the acid in the presence of a mild acid as a catalyst to produce a discrete stanol/sterol ester represented by the formula 1: wherein R1 is a C6-C23 carbon chain; and R2 is a C3-C15 carbon chain. A melted fatty acid is used as a solvent and the mild acid is NaHSO4. The sterol/stanol-ester is added in an amount of more than about 98 wt.%. The reaction temperature is in the range from about 100°C to about 200°C. The reaction is performed under vacuum.
During the four months of active experimental condition, adolescents receive five sessions of the youth aware of mental health program in the class room, and one additional session on NSSI. Parents and school staff receive an online psychoeducation on NSSI. School health care personnel receive a 2-day workshop on NSSI and suicidality.
The present invention provides a new type spraying agent 'biological active spraying agent' which is prepared from raw material of Chinese traditional medicine and technology of bio-fermentation for treating and preventing asthma. The spraying agent is the extract juice processed by bio-fermentation technology with raw material suncured ginseng. The Chinese traditional medicine bio-fermentation agent majors breakthrough in treating asthma. Patient can relieve a cough after inhalation 5-15 minutes. The spraying agent has advantage of micro-method Chinese traditional medicine after processed by bio-fermentation technology, each spray inhalation amount contains 0.03-0.09g of raw medicine, and enhances treating effect of compount Chinese traditional medicine, saves the Chinese traditional medicine resource. The spraying agent has merits of convenient administration, convenient carrying, good taste, good color, non-toxic side effect, low cost, suitable for all. The spraying agent can single treat asthma whole course, and eliminates the dependency to glucocorticoids and antibiotics. The spraying agent is a great invention in medicine research field.
Active recovery program without blood flow restriction using a periodization methodology in soccer. (Post-match +1 training).
PURPOSE:To obtain a reverse transcriptase inhibitor having a strong inhibitory effect on a reverse transcriptase produced by HIV and useful for improvement and prevention of AIDS and for suppression or retardation of the crisis after infection with AIDS virus. CONSTITUTION:There is provided a reverse transcriptase inhibitor containing 2'-deoxy-L-ribonucleotide-5'-triphosphate, preferably 2'-deoxy-L-thymidine-5'- triphosphate as the active component and having a strong inhibitory effect on a reverse transcriptase produced by retrovirus. This compound can be produced by converting an L-nucleotide (an optical antipode of a natural type nucleotide) into its monophosphate, e.g. in the presence of phosphorus oxychloride and subsequently synthesizing its corresponding 5'-triphosphate compound therefrom, e.g. according to phosphorimidazolidate method. This compound is also useful as a regent for studies in the fields of biochemistry, genetic engineering etc.
FIELD: medicine, clinical pharmacology. SUBSTANCE: invention relates to the method of pharmacological correction of disturbances in energetic metabolism in the brain. Bergenia crassifolia leaves extract is used as a cerebroprotecting agent in encephalopathy. An agent shows high specific activity and low adverse effects due to its low toxicity. EFFECT: enhanced effectiveness of an agent. 2 tbl, 2 ex
A single dose of 185mg of levetiracetam administered orally to participants. Participants undergo a 15-minute MRI scan using arterial spin labeling (ASL) before dosing and two hours post-dosing.
Standardized mite allergenic extracts are intended for use in the diagnosis and therapy of D.farinae and D.pteronyssinus mite allergy, as established by allergy history and skin test reactivity (6,10). Standardized Mite extracts are not interchangeable with non standardized mite extracts. To select patients for a confirmation of allergic disease diagnosis and/or treatment with allergen extracts, screening tests should be done using in vivo identification testing methods (i.e. scratch or intradermal testing).(13)

Standardized mite extract containing equal parts of D.farinae and D.pteronyssinus is intended for therapy only. The use of standardized mites extract is indicated for hypersensitization treatment and may be used as part of the over-all management of the allergic patient. This treatment is particularly to be recommended when a patient's sensitivity to mite has been determined initially by scratch or intradermal skin tests.
Cases of hemorrhagic events, including central nervous system, respiratory, and gastrointestinal hemorrhage, have been reported in clinical trials with KADCYLA. Some of these bleeding events resulted in fatal outcomes. In EMILIA, the overall incidence of hemorrhage was 32% in the KADCYLA-treated group and 16% in the lapatinib plus capecitabine-treated group. The incidence of Grade ≥ 3 hemorrhage was 1.8% in the KADCYLA-treated group and 0.8% in the lapatinib plus capecitabine-treated group. In KATHERINE, the overall incidence of hemorrhage was 29% in the KADCYLA-treated group and 9% in the trastuzumab-treated group. The incidence of Grade ≥ 3 hemorrhage was 0.4% in the KADCYLA-treated group, with one fatal case of intracranial hemorrhage, and 0.3% in the trastuzumab-treated group [see Adverse Reactions (6.1)]. Although, in some of the observed cases the patients were also receiving anti-coagulation therapy, antiplatelet therapy, or had thrombocytopenia, in others there were no known additional risk factors. Use caution with these agents and consider additional monitoring when concomitant use is medically necessary.
Intraluminal medical devices, systems and methods are provided. In one embodiment, an intraluminal medical system includes a handheld interface device in communication with an intraluminal device to be positioned within a body lumen of a patient. The intraluminal device includes a sensor configured to obtain physiology data associated with the body lumen. The handheld interface device includes a housing sized and shaped for handheld use, a controller core disposed within the housing and configured to control a plurality of sensor types respectively associated with a plurality of intraluminal devices, a computing core disposed within the housing, and a first display integrated in the housing. The controller core is operable to identify the sensor of the intraluminal device, and control the sensor to obtain the physiology data associated with the body lumen. The computing core is operable to process the physiology data using instructions associated with the identified sensor, wherein the computing core is further operable to process physiology data associated with the plurality of sensor types respectively using a plurality of modality specific instructions; and generate a graphical representation based on the physiology data. The first display is operable to display the graphical representation based on the physiology data.
Oligonucleotides are provided which are capable of antisense interaction with messenger RNA of papillomavirus. Such oligonucleotides or oligonucleotide analogs can be used for diagnostics and therapeutics as well as for research purposes. In accordance with preferred embodiments of this invention, oligonucleotides are provided which are hybridizable with selected messenger RNA from a human papillomavirus. The oligonucleotide is able to inhibit the function of the RNA, and accordingly is useful for therapy for infections by such papillomavirus. In accordance with a preferred embodiment, portions of the papillomavirus are targeted for antisense attack. Thus, oligonucleotides are preferably provided which hybridize with the E2, E6 and E7 messenger RNAs.
An orally administered fatty acid composition for the treatment of cardiovascular diseases, and a method of treating same, are provided. The composition may include at least one omega-3 fatty acid amide, and/or at least one omega-3 fatty acid plus ethanolamine, and at least one tocotrienol. The composition may include 5Z,8Z,l lZ,14Z,17Z-eicosapentaenoic ethanolamide (EPA ethanolamide), 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic ethanolamide (DHA ethanolamide), and at least one tocotrienol. The EPA ethanolamide and the DHA ethanolamide are preferably each substantially in a range of 100 - 900 mg per dosage form. The at least one tocotrienol is substantially in a range of 10 - 500 mg per dosage form. The at least one tocotrienol includes at least one of α-tocotrienol, β- tocotrienol, γ-tocotrienol, or δ-tocotrienol and is preferably substantially tocopherol- free. The composition may take the form of a medical food or a pharmaceutical preparation. A preferred formulation of the composition includes approximately 525 mg EPA ethanolamide, approximately 315 mg DHA ethanolamide, and approximately 50 mg δ-tocotrienol. The EPA and DHA ethanolamides may be synthesized from fatty acid triglycerides.
This study explores the effects of bodily states on emotions based on embodied cognition theories of conceptual metaphor and feelings-as-information theory. Specifically, it investigates how physical suffocation induced by mask-wearing affects perceptions of emotional suffocation related to one's romantic relationship and financial situation. In this quantitative online experiment, we employed a convenience sampling method through a crowdsourcing platform. Adult participants (N = 180, 25 years or older and involved in a romantic relationship) were randomly assigned to three conditions: wearing COVID-19 masks properly, wearing masks on their chins, or not wearing masks. After completing a puzzle meant to prolong mask-wear, participants filled out digital questionnaires assessing their experiences of physical and psychological distress. The results supported our proposed mechanisms, revealing that increased feeling of physical suffocation while wearing masks properly, compared to the other conditions, was linked to heightened feelings of financial and romantic distress, supporting the conceptual metaphor account. This link was partially mediated by elevated state anxiety, aligning with the feelings-as-information theory. This study demonstrates how bodily experiences can impact emotional states, and highlights the complex interplay between everyday behaviours like mask-wearing and emotions.
Exposure to industrial contaminants has been implicated in neurobehavioral toxicity in humans. To explore this potential risk, we investigated the neurotoxic effects of oral exposure to a complex groundwater mixture containing petroleum hydrocarbons, pesticides, heavy metals, and unknown parent and breakdown products using male and female Sprague Dawley rats. Rats were randomly divided into six groups and orally exposed daily via drinking water to: (i) tap water, (ii) 10 % v/v low impact groundwater, and (iii) 0.01 %, 0.1 %, 1 %, and 10 % high-impact groundwater for 60 days. Medium- and long-term memory (measured using the novel object recognition task) were impaired. However, no gross motor or coordination deficits were observed by the end of the study period (rotarod test). Doppler ultrasound of the middle cerebral and common carotid arteries was performed to examine the hemodynamic changes. The common carotid blood flow decreased in the groundwater-exposed rats compared to that in the control. However, no significant differences in cerebral blood velocity were observed between the exposed and control groups. A significant reduction in hippocampal serotonin levels was observed in groundwater-exposed rats relative to that in the control group. Collectively, these results indicate that impaired recognition memory in rats exposed to groundwater is accompanied by reduced cranial blood flow and hippocampal neurotoxicity, characterized by altered serotonergic signalling. The levels of detected contaminants known to cause neural or vascular damage were of magnitudes lower than the concentrations of contaminants found in the groundwater mixture, meaning the culprit chemical identity remains unknown. This study emphasizes the need to use whole mixture in exposures when dealing with complex contaminated sites rather than the use of individual compounds.
In vitro and in vivo studies in animals suggest that escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine and dopamine neuronal reuptake. Escitalopram is at least 100 fold more potent than the R-enantiomer with respect to inhibition of 5-HT reuptake and inhibition of 5-HT neuronal firing rate. Tolerance to a model of antidepressant effect in rats was not induced by long-term (up to 5 weeks) treatment with escitalopram. Escitalopram has no or very low affinity for serotonergic (5-HT 1-7) or other receptors including alpha- and beta-adrenergic, dopamine (D 1-5), histamine (H 1-3), muscarinic (M 1-5), and benzodiazepine receptors. Escitalopram also does not bind to, or has low affinity for, various ion channels including Na +, K +, Cl -, and Ca ++ channels. Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular side effects of other psychotropic drugs.